Assessment of the timing of histologic and molecular testing indicates that testing occurred prior to treatment initiation for most patients with metastatic non—small cell lung cancer.
Jack Mardekian, PhD
Advertisement
Articles by Jack Mardekian, PhD
This study identified inefficiencies in drug and medical service utilization related to pain management among Medicare members with osteoarthritis and chronic low back pain.
Advertisement
Latest Updated Articles
- Molecular Testing Patterns in Metastatic Non—Small Cell Lung Cancer
February 3rd 2016
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
4
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
5